Stay updated on ORION-01 Oregovomab & Nivolumab Clinical Trial

Sign up to get notified when there's something new on the ORION-01 Oregovomab & Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ORION-01 Oregovomab & Nivolumab Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dose level for Oregovomab in combination with Nivolumab in a phase Ib/IIa clinical trial for patients with recurrent epithelial ovarian cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:16.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the need for signed informed consent and the ability to comply with study requirements. Previously, this section had no information provided.
    Difference
    59%
    Check dated 2024-05-22T21:35:33.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:34:59.000Z thumbnail image

Stay in the know with updates to ORION-01 Oregovomab & Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ORION-01 Oregovomab & Nivolumab Clinical Trial page.